This FierceVaccines special report spotlights 10 promising therapeutic vaccines on their way through clinical development that might just change the face of cancer treatment. Many of them are in the early steps of R&D, so it may be a while, especially for those that are first-in-class, or that are bringing a new technology to the table, but they could be the first baby steps to a brave new world.
Chubby mice quickly shed 10% of their body weight when injected with modified somatostatin, a peptide hormone.
Vaccibody's lead therapeutic DNA vaccine, developed for the treatment of precancerous changes in the cervix caused by human papillomavirus (HPV) infection, is expected to move into the clinic in late 2013 once funding is in place, the company CEO Ole Henrik Brekke told FierceVaccines at BIO 2012.
Parkinson's disease is an incurable disorder that affects the brain and nervous system, leading to problems with movement and cognition. Available treatments help the symptoms but do not slow the progression of the disease; however, a therapeutic vaccine that has begun clinical trials with developer AFFiRiS could modify the disease process itself.
Creating vaccines that bind to a damaged cell-recognition molecule called Clec9A could trick dendritic cells into thinking they have encountered a damaged cell and help to launch an immune response.
As vaccine targets expand beyond communicable diseases, the New York Times notes that vaccines could hold promise for millions who suffer from addiction. While none have been approved, the potential
Researchers at the University of Leeds and the Mayo Clinic have developed an immunotherapeutic vaccine that has shown promising results for curing prostate cancer in mice. But Reuters notes that
Aduro BioTech has gained access to BioSante Pharmaceuticals' GVAX pancreas cancer vaccine and GVAX prostate cancer vaccine through a licensing agreement. The Berkeley, CA-based company plans to
A translational team of experts in Europe say they have identified a protein which is produced naturally in the human body and can be used as a therapeutic vaccine capable of fighting a range of
Halifax, Nova Scotia-based Immunovaccine will focus the Phase I/II clinical development plan for DPX-Survivac on ovarian cancer. The decision is based on positive input from leaders in cancer